Large Eczema Area and Severity Index response at 2-year follow-up of patients treated with dupilumab in routine care of atopic dermatitis: results from the national registry TREATgermany
Year: 2025
Type: article
Study design: Observational Study
Abstract: The TREATgermany registry was set up in 2016. We provide results on long-term dupilumab therapy in adults with moderate and severe atopic dermatitis (AD) in a routine care setting. The analysis cohort of 294 patients is one of the largest cohorts with 2-year follow-up data on treatment effects of dupilumab obtained from an AD registry to date. We report the Harmonising Outcome Measures for Eczema (HOME) core outcome set. The Eczema Area Severity Index (EASI) 75 and EASI 90 response rates for patients on treatment at month 24 were 78.8% and 51.2%, respectively.
Source: Skin Health and Disease
Authors: Luise Heinrich, Thomas Birkner, Susanne Abraham, Sascha Gerdes, Tatjana Honstein, Sigrid Müller, Matthias Augustin, Inken Harder, Thomas Schaefer, Andreas Pinter, Anne Bong, Jutta Ramaker-Brunke, Tilo Biedermann, Michael Sticherling, Hannah Gorriahn-Maiterth, Knut Schäkel, Beate Schwarz, Sven Quist, Mohammad Asefi, Nicole Adler, Maren Stahl, Michael Schulz-Kiesow, Florian Schenck, Thomas Werfel, Stephan Weidinger, Annice Heratizadeh, Jochen Schmitt
Institutions: University Hospital Carl Gustav Carus, Zentrum für Evidenzbasierte Gesundheitsversorgung, Technische Universität Dresden, University Hospital Schleswig-Holstein, Medizinische Hochschule Hannover, Universität Hamburg, University Medical Center Hamburg-Eppendorf, University Hospital Frankfurt, Jungheinrich (Germany), Technical University of Munich, Universitätsklinikum Erlangen, University Hospital Heidelberg, Instituto de Dermatologia Dona Libania, Dermatrials Research
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,597
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Biogen, Celgene, Hexal AG, Regeneron Pharmaceuticals, Les Laboratories Pierre Fabre, Dermira, Mylan, Incyte, Argenx, European Commission, Technische Universität Dresden, Medizinischen Hochschule Hannover, Technische Universität München, Galderma, Gemeinsame Bundesausschuss, Medac, Lilly Deutschland, Sanofi Australia, LEO Pharma, Principia Biopharma, UCB Pharma, Cilag
OpenAlex ID: W4414715744